Martín, Miguel http://orcid.org/0000-0001-9237-3231
Carrasco, Eva
Rodríguez-Lescure, Álvaro
Andrés, Raquel
Servitja, Sonia
Antón, Antonio
Ruiz-Borrego, Manuel
Bermejo, Begoña
Guerrero, Ángel
Ramos, Manuel
Santaballa, Ana
Muñoz, Montserrat
Cruz, Josefina
Lopez-Tarruella, Sara
Chacón, Jose I.
Álvarez, Isabel
Martínez, Purificación
Miralles, Juan J.
Polonio, Óscar
Jara, Carlos
Aguiar-Bujanda, David
Funding for this research was provided by:
LILLY
Article History
Received: 27 March 2023
Accepted: 29 May 2023
First Online: 20 June 2023
Declarations
:
: Dr. Miguel Martín has received consulting fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology and Pfizer; speakers’ honoraria from AstraZeneca, Amgen, Roche/Genentech, Novartis, Daiichi Sankyo, and Pfizer; and contracted research fees from Roche, Novartis, and PUMA. Eva Carrasco has stock and other ownership interests from Lilly, has received travel and accommodations support from Roche and her husband has participated in consulting and advisory board activities with Bristol-Myers Squibb, Novartis, Celgene, Roche Pharma, Janssen, Amgen, Incyte, Abbvie and Pfizer, has received travel and accommodations support from Celgene, Novartis and Bristol-Myers Squibb. His institution has received research funding from Celgene, Janssen, Bristol-Myers Squibb, Novartis, Celgene, Roche/Genentech, Amgen, Pfizer and Abbvie. GEICAM has received research funding from Roche/Genentech, Bristol-Myers Squibb, Novartis, Pfizer, Celgene, AstraZeneca, Merck Sharp & Dohme, Pierre Fabre and Takeda. Dr. Ángel Guerrero has received institutional grant by Pfizer, advisory by Novartis, Palex, Pfizer, AstraZeneca, Pierre Fabre, travel grant by Roche Pharma, Pfizer and Novartis and speaker honoraria by Novartis, Pfizer, Lilly, Pfizer, AstraZeneca. Dr. Ana Santaballa has received advisory by Pfizer. Dr. Josefina Cruz has received speaker honoraria by Astrazeneca, Roche Pharma, Novartis, PharmaMar, Pierre Fabre, Eisai, Lilly, Daiichi Sankyo, Seagen, Gilead and Pfizer and advisory by Astrazeneca, Roche Pharma, Novartis, PharmaMar, Eisai, Lilly, GlaxoSmithKline, Pfizer, Gilead, Seagen and Daiichi Sankyo. Dr. Sara Lopez-Tarruella has received advisory by AstraZeneca, Novartis, Roche Pharma, Pfizer, Pierre Fabre, Lilly, Seagen, Daiichi Sankyo Europe GmbH, Gilead Sciences, MSD, GlaxoSmithKline, Veracyte and speaker honoraria by Lilly. The rest of the authors have no conflicts of interest.
: The study protocol of the original clinical trials was approved by an institutional review board and the national regulatory agency.
: Informed consent was obtained from all individual participants included in the study. The current study was approved by an institutional review board.